Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly Total Current Liabilities came in at $89.5 million in Q1 2026, up 34.31% year-on-year from $66.6 million in Q1 2025, and down 9.82% quarter-over-quarter from $99.2 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $89.5 million for Q1 2026.
- On a quarterly basis, Total Current Liabilities rose 34.31% year-over-year to $89.5 million in Q1 2026; TTM through Mar 2026 was $89.5 million, a 34.31% increase from a year earlier, with the FY2025 full-year figure at $99.2 million, up 56.77% from the prior year.
- Total Current Liabilities declined to $89.5 million in Q1 2026 per RIGL's latest filing, from $99.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $99.2 million in Q4 2025 and bottomed at $44.0 million in Q2 2023.
- The 5-year median for Total Current Liabilities is $59.2 million (2022), against an average of $64.9 million.
- Across the five-year window, Total Current Liabilities retreated 23.14% in 2023 and soared 73.81% in 2025, its largest moves.
- Year by year, Total Current Liabilities stood at $65.2 million in 2022, then declined by 18.32% to $53.3 million in 2023, then grew by 18.83% to $63.3 million in 2024, then jumped by 56.77% to $99.2 million in 2025, then decreased by 9.82% to $89.5 million in 2026.
- Per Business Quant, the three latest RIGL Total Current Liabilities figures stand at $89.5 million (Q1 2026), $99.2 million (Q4 2025), and $94.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Rigel Pharmaceuticals | 681.25 Mn | 534.56 Mn | 54.21 Mn | 89.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.49 Mn |
| Dec 31, 2025 | 99.24 Mn |
| Sep 30, 2025 | 94.40 Mn |
| Jun 30, 2025 | 86.64 Mn |
| Mar 31, 2025 | 66.63 Mn |
| Dec 31, 2024 | 63.30 Mn |
| Sep 30, 2024 | 54.31 Mn |
| Jun 30, 2024 | 58.65 Mn |
| Mar 31, 2024 | 73.20 Mn |
| Dec 31, 2023 | 53.27 Mn |
| Sep 30, 2023 | 48.27 Mn |
| Jun 30, 2023 | 44.02 Mn |
| Mar 31, 2023 | 45.52 Mn |
| Dec 31, 2022 | 65.21 Mn |
| Sep 30, 2022 | 47.27 Mn |
| Jun 30, 2022 | 54.96 Mn |
| Mar 31, 2022 | 59.23 Mn |
| Dec 31, 2021 | 63.55 Mn |
| Sep 30, 2021 | 59.28 Mn |
| Jun 30, 2021 | 59.54 Mn |